Illumina launches MicroRNA assay for gene expression profiling

Illumina, Inc. today launched a MicroRNA Assay for Gene Expression profiling. Priced at $95 per sample, this assay is the only solution available to allow rapid and reproducible miRNA expression profiling at a price less than half that of other commercially available methods.

By developing a high-density expression array with content from the miRBase Sequence Database this new tool will help researchers better understand the role microRNAs (miRNA) play in regulating messenger RNA (mRNA).

According to Robert C. Thompson, Ph.D., Assistant Professor, Molecular and Behavioral Neuroscience Institute at University of Michigan, “miRNAs are of profound interest to me given the level of regulation that brain cells have at the transcriptional and post-transcriptional levels. Illumina’s new MicroRNA Assay is a solution ideally suited for high throughput analysis of brain samples, which meets my need for an application that utilizes small amounts of total RNA while generating reliable results.”

With the new MicroRNA Assay for Gene Expression profiling, coupled with the recently launched Digital Gene Expression Profiling and Small RNA Analysis applications, Illumina provides the most comprehensive array and sequencing-based gene expression tool kit in the industry. Using a Digital Gene Expression approach, researchers can discover new miRNAs without prior sequence information. For high-throughput studies that validate and profile miRNA researchers can take advantage of the array-based miRNA solution.

“We are offering miRNA products at half of the cost of other commercially available methods so that researchers can conduct larger studies at a price they can afford,” said Tanya Boyaniwsky, Illumina’s Marketing Manager for Gene Expression. “We are committed to regularly updating these products with newly discovered miRNAs as well as information from internal small RNA discovery projects conducted on Illumina’s Genome Analyzer.”

Compared to traditional mRNA-based gene expression approaches, miRNA profiling has distinct advantages: A single miRNA can regulate the expression of several genes and could produce larger effects that more clearly influence a disease state. With only approximately 1,000 miRNAs predicted in humans, compared to 30,000 mRNAs per cell, miRNAs represent a rich pool of potential diagnostic biomarkers. In addition, miRNAs are less likely to be degraded in formalin-fixed, paraffin-embedded (FFPE) samples or other RNA samples of poor quality. For these reasons, miRNA profiling is vital to the study of developmental biology, stem cell characterization, biomarker discovery, oncogenesis, therapeutic effects, viral infection processes and many other areas of fundamental and applied biology.

http://www.illumina.com/

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Illumina, Inc.. (2018, July 27). Illumina launches MicroRNA assay for gene expression profiling. News-Medical. Retrieved on December 22, 2024 from https://www.news-medical.net/news/2007/10/22/31503.aspx.

  • MLA

    Illumina, Inc.. "Illumina launches MicroRNA assay for gene expression profiling". News-Medical. 22 December 2024. <https://www.news-medical.net/news/2007/10/22/31503.aspx>.

  • Chicago

    Illumina, Inc.. "Illumina launches MicroRNA assay for gene expression profiling". News-Medical. https://www.news-medical.net/news/2007/10/22/31503.aspx. (accessed December 22, 2024).

  • Harvard

    Illumina, Inc.. 2018. Illumina launches MicroRNA assay for gene expression profiling. News-Medical, viewed 22 December 2024, https://www.news-medical.net/news/2007/10/22/31503.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Illumina partners with centers across France to advance a precision medicine approach for patients with late-stage cancer